FDA
-
-
-
-
-
-
-
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
-
-
-
-
-
-
-
Enlivex closes $212 million private placement for digital asset strategy
-
-
-
-
-
-
-
Enlivex (ENLV) Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
-
-
-
-
-
-
-
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
-
-
-
-
-
-
-
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
-
-
-
-
-
-
-
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Pre-Open Movers 08/25: (OVID) (GPS) (CRM) Higher; (PLCE) (POR) (PANW) Lower (more...)
-
335,203 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


